Rocket Pharmaceuticals, Inc. (RCKT)
| Market Cap | 405.72M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -257.30M |
| Shares Out | 107.90M |
| EPS (ttm) | -2.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 54,874,663 |
| Open | 3.830 |
| Previous Close | 2.910 |
| Day's Range | 3.141 - 4.100 |
| 52-Week Range | 2.190 - 22.010 |
| Beta | 0.65 |
| Analysts | Buy |
| Price Target | 12.96 (+244.68%) |
| Earnings Date | Aug 7, 2025 |
About RCKT
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for RCKT stock is "Buy." The 12-month stock price target is $12.96, which is an increase of 244.68% from the latest price.
News
Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.
The past year has been a disappointing one for gene therapies.
FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy
Rocket Pharmaceuticals Inc. RCKT stock is trading higher on Wednesday after the U.S. Food and Drug Administration (FDA) lifted the clinical hold on its pivotal Phase 2 trial of RP-A501 for Danon disea...
US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial
Rocket Pharmaceuticals said on Wednesday that the U.S. Food and Drug Administration has lifted the clinical hold on its gene therapy mid-stage trial.
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...
DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025
PHILADELPHIA , Aug. 8, 2025 /PRNewswire/ -- Berger Montague PC , a leading Philadelphia-based law firm representing investors, announces that a securities class action lawsuit has been filed against ...
Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Opt...
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
In May, FDA Commissioner Marty Makary named Vinay Prasad the next director of the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER). Within three months, Pr...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Opt...
Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours
Rocket Pharmaceuticals, Inc. RCKT, a firm focused on developing cardiovascular gene therapy, announced a strategic corporate reorganization to extend its runway.
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. Lawsuit – RCKT
NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT).
Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop
PHILADELPHIA , July 9, 2025 /PRNewswire/ -- Berger Montague PC , a nationally recognized securities litigation firm based in Philadelphia, announces it is investigating a newly filed securities class...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Lawsuit - RCKT
NEW YORK , July 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during ...
Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...
Rocket Pharmaceuticals, Inc. (RCKT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Com...
Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Com...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Com...